Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alnylam Pharmaceuticals (NQ: ALNY ) 277.33 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Alnylam Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 10 Next > Analyst Expectations for Alnylam Pharmaceuticals's Future December 08, 2023 Via Benzinga Why Newly Listed Korro Bio Shares Are Gaining Today December 04, 2023 H.C. Wainwright initiated coverage on Korro Bio Inc (NASDAQ: KRRO), a biotech company developing genetic medicines focused on editing ribonucleic acid (RNA) to treat various diseases. Via Benzinga Expert Ratings for Alnylam Pharmaceuticals November 15, 2023 Via Benzinga Earnings Outlook For Alnylam Pharmaceuticals November 01, 2023 Via Benzinga Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing October 18, 2023 The company can begin a pivotal study of its treatment for cardiomyopathy. Via Investor's Business Daily Expert Ratings for Alnylam Pharmaceuticals October 16, 2023 Via Benzinga 10 Health Care Stocks Whale Activity In Today's Session October 11, 2023 Via Benzinga Analyst Expectations for Alnylam Pharmaceuticals's Future September 29, 2023 Via Benzinga What 16 Analyst Ratings Have To Say About Alnylam Pharmaceuticals September 12, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2023 October 11, 2023 Via Benzinga CSX To Rally Around 27%? Here Are 10 Other Analyst Forecasts For Wednesday October 11, 2023 Morgan Stanley cut Netflix, Inc. (NASDAQ: NFLX) price target from $450 to $430. Morgan Stanley analyst Benjamin Swinburne maintained an Equal-Weight rating. Netflix shares rose 0.8% to $375.51 in... Via Benzinga The Latest Analyst Ratings for Alnylam Pharmaceuticals August 16, 2023 Via Benzinga Analyst Expectations for Alnylam Pharmaceuticals's Future July 25, 2023 Via Benzinga Why Is Genetic Disease-Focused Alnylam Pharmaceuticals Stock Trading Lower Today? October 09, 2023 The FDA has issued a Complete Response Letter (CRL) to Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) supplemental New Drug Application (sNDA) for patisiran for cardiomyopathy of transthyretin- Via Benzinga Exposures Product Safety Alnylam Stock Crumbles After The FDA Unexpectedly Rejects Its Heart Drug October 09, 2023 Shares skidded to their lowest point since September on the FDA's rejection. Via Investor's Business Daily Exposures Product Safety 2 Growth Stocks That Could Rocket Higher Before the End of 2023 October 08, 2023 Potential approvals of new medicines expected soon could push these stocks through the roof. Via The Motley Fool 10 Health Care Stocks Whale Activity In Today's Session October 05, 2023 Via Benzinga Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges September 27, 2023 Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 29, 2023 September 29, 2023 Via Benzinga Potential Label Restrictions Loom For Alnylam's Patisiran Despite Approval Prospects September 14, 2023 On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. Via Benzinga Exposures Product Safety Alnylam Pharma Tumbles After FDA Advisors Dash Its Hopes Of Rivaling Pfizer September 14, 2023 Its heart disease drug could gain approval, but FDA advisors don't expect it to take on Pfizer's leading drug. Via Investor's Business Daily Exposures Product Safety Despite FDA Doubts, Adcomm Backs Alnylam's Gene Silencing Therapy For Expanded Use Into Rare Heart Disease September 14, 2023 On Wednesday, an FDA advisory committee voted 9-3 in favor of Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) patisiran. Via Benzinga Exposures Product Safety Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going September 14, 2023 US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data. Via Benzinga Topics Economy Stocks Exposures Interest Rates US Equities Buy List Alert: 3 Pharma Stocks with Positive Trial Updates September 13, 2023 These three pharma stocks could be driven higher amidst future revenue prospects as they report to investors positive clinical developments. Via InvestorPlace Here's How Much $1000 Invested In Alnylam Pharmaceuticals 5 Years Ago Would Be Worth Today September 11, 2023 Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session September 08, 2023 Via Benzinga Cramer Says 'Please Stay Away' From This EV Maker, It 'Should Not Be Public' September 08, 2023 On CNBC’s "Mad Money Lightning Round," Jim Cramer said Norfolk Southern Corporation (NYSE: NSC) is the "cheapest I’ve seen in a very long time, Via Benzinga Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope September 07, 2023 Alnylam Pharmaceuticals Inc's (NASDAQ: ALNY) KARDIA-1 Phase 2 study of zilebesiran, an investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for hypertension, Via Benzinga Here's How Much $100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth Today September 05, 2023 Via Benzinga Analyst Upgrades Ionis Pharmaceuticals To Buy Amid Key Pipeline Developments: Eplontersen And Donidalorsen Show Promising Outlook July 31, 2023 Citi analyst upgraded Ionis Pharmaceuticals Inc (NASDAQ: IONS) from Neutral to Buy with a price target of $60, increased from $36, citing multiple key Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 10 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.